Onxeo Announces Its Financial Calendar for 2017

PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE)-- Regulatory News:

Onxeo S.A. (Paris: ONXEO) (NASDAQ OMX: ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced its financial calendar for 2017:

March 7, 2017					Full-year 2016 consolidated accounts
April 26, 2017					General shareholders’ meeting (to be convened in Paris)
April 27, 2017					Quarterly information as of March 31, 2017
July 28, 2017					Consolidated accounts for the 1st half of 2017
October 26, 2017					Quarterly information as of September 30, 2017

This financial calendar is for indicative purposes only and Onxeo could change its publication dates should it deem it necessary.

About OnxeoOnxeo is a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, driven by high therapeutic demand in one of the fastest growing segments of the pharmaceutical industry. Onxeo’s objective is to become a major international player in the field of rare cancers. Its growth strategy is founded on the development of innovative, effective, and safe drugs based on breakthrough technologies that can make a real difference in the treatment of orphan oncology diseases and considerably improve the quality of life of patients affected by rare and aggressive cancers. Onxeo’s comprehensive portfolio features a broad orphan oncology pipeline, with four independent programs in various stages of clinical development, including Onxeo’s first approved orphan oncology drug, Beleodaq®. The Company is headquartered in Paris, France and has approximately 50 employees. Onxeo is listed on Euronext in Paris, France (Ticker: ONXEO, ISIN Code: FR0010095596) and Nasdaq Copenhagen, Denmark (Ticker: ONXEO).

Onxeo’s orphan oncology products are:

• Livatag® (Doxorubicin Transdrug™): Currently being evaluated in a Phase III trial (ReLive) in patients with hepatocellular carcinoma (primary liver cancer); Livatag is also under exploratory preclinical development to assess interest of its combination with other anti cancer agents.
• Beleodaq® (belinostat): FDA-approved in the US in 2014 under the agency’s accelerated approval program as a second-line treatment for patients with peripheral T-cell lymphoma (PTCL) and currently marketed by Onxeo’s partner in the US, Spectrum Pharmaceuticals; belinostat in combination with other cancer agents is currently in development in first-line treatment for patients with PTCL (BelCHOP) and a oral formulation is under development.
• AsiDNA: first-in-class siDNA (signal-interfering DNA) which has successfully undergone a proof-of-concept Phase I trial in metastatic melanoma via local administration
• Validive® (Clonidine Lauriad®): Positive final results from a Phase II trial in head and neck cancer patients with severe oral mucositis

In addition, Onxeo has successfully developed and registered two non-cancer products, which are currently being commercialized in the U.S. and Europe.

Learn more by visiting www.onxeo.com.

To receive our press releases and newsletters, please register on: http://www.onxeo.com/en/newsletter/Follow us on Twitter: @Onxeo_

DisclaimerThis communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2015 Reference Document filed with the AMF on April 29, 2016, which is available on the AMF website (http://www.amf-france.org) or on the company’s website (www.onxeo.com).

View source version on businesswire.com: http://www.businesswire.com/news/home/20161207005644/en/

Onxeo S.A.
Judith Greciet, CEO
Nicolas Fellmann, CFO
+33 1 45 58 76 00
[email protected]
or
Alize RP (France)
Caroline Carmagnol / Florence Portejoie
+33 6 64 18 99 59 / +33 6 47 38 90 04
[email protected]
or
The Ruth Group (U.S.)
Kirsten Thomas / Lee Roth
+1 508 280 6592 / +1 646 536 7012
[email protected] / [email protected]

Source: Onxeo S.A.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Uzbekistan Hosts 38th International Olympiad in Informatics, Cementing Role as Central Asia’s Leading IT Hub
• Poolside Infrastructure Company Announces New CFO Justin Lagasse
• Medical Solutions ranks among nation's Top 5 largest healthcare staffing firms